Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/14/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
   |
23 |
| 08/14/23 | 8-K | Current report filing |
|
|
5 |
| 08/09/23 | EFFECT | Notice of Effectiveness |
|
1 | |
| 08/09/23 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
8 | |
| 08/07/23 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 08/07/23 | ARS | Annual report to security holders |
|
127 | |
| 08/07/23 | DEF 14A | Definitive proxy statements |
|
20 | |
| 08/07/23 | SC 13G/A | Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions |
|
5 | |
| 08/03/23 | UPLOAD | SEC-generated letter |
|
1 | |
| 07/28/23 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
17 |
